Bevacizumab Biosimilars in 2024: Analyzing Market Potential and Forecasts
  Bevacizumab - Biosimilars Insight, 2024 Bevacizumab, a monoclonal antibody developed by Genentech and marketed under the brand name Avastin, has been a significant player in the oncology landscape since its approval. It is primarily used for treating various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma multiforme. The drug works by...
0 Comentários 0 Compartilhamentos 516 Visualizações 0 Anterior
Patrocinado